Castle biosciences inc.

Castle Biosciences, Inc. is a commercial-stage diagnostics company. The Company is focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes. Its portfolio consists of tests for skin cancers, uveal melanoma ...Contact Us. Lab and Corporate Office addresses. Customer Service contact info. Media Contacts.FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced upcoming presentations on ...Jun 23, 2019 · Our History. Castle Biosciences was founded by Derek Maetzold who believed that traditional methods to determine cancer patients’ prognosis could be improved by newly emerging techniques in molecular biology. We continue to focus on transforming disease management in areas of unmet clinical need through the development and marketing of ...

Castle Biosciences Inc’s price is currently down 25.04% so far this month. During the month of October, Castle Biosciences Inc’s stock price has reached a high of $16.84 and a low of $12.07. Over the last year, Castle Biosciences Inc has hit prices as high as $29.59 and as low as $9.26.

Castle Biosciences’ DecisionDx-CM Seq is a 3-gene test that uses next-generation sequencing (NGS) to identify somatic mutations relevant to cutaneous melanoma in melanoma tumor tissue. The test includes hotspot mutations in the genes BRAF, NRAS, and KIT. Mutations in these genes are important to help inform therapy choices for melanoma ...Get the latest Castle Biosciences Inc (CSTL) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and …

Castle Biosciences Customer Service Email: [email protected] Call: (412) 820-3050 Billing and Insurance Questions Email: [email protected] Call: 866-788-9007, option #3 For additional information about Castle Biosciences or TissueCypher testing, please go to: …Apr 4, 2022 · Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced it has signed a definitive agreement to acquire AltheaDx, Inc. (AltheaDx). AltheaDx is a commercial-stage molecular diagnostics company specializing in the field of pharmacogenomics (PGx) testing services that ... castle biosciences, inc. EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (this “ Agreement ”) is entered into as of October 1, 2008 (the “ Effective Date ”) by and between Castle Biosciences, Inc., a Delaware corporation (the “ Company ”), and Toby Juvenal (“ Executive ”) (collectively referred to as the ...Castle Biosciences, Inc. (NASDAQ:NASDAQ:CSTL) Q1 2023 Earnings Conference Call May 3, 2023 4:30 PM ETCompany ParticipantsCamilla Zuckero - Vice President,...Tracfone Wireless Inc has been a leading player in the telecommunications industry, offering innovative solutions and cutting-edge technology to its customers. With a focus on providing reliable and affordable wireless services, Tracfone ha...

Castle Creek is a portfolio company of Paragon Biosciences, which founded Castle Creek with the vision to deliver transformative therapies to patients with rare genetic dermatologic diseases ...

Christopher Ballas is Chief Technology Officer at Castle Creek Biosciences, Inc. He has over 25 years of experience with cell and gene therapies in academic and industry roles covering research, development, testing, and manufacturing of viral vectors and cell therapies. Dr. Ballas recently was the Sr. Vice President of Manufacturing for Innovative …

Are you yearning for adventure, breathtaking landscapes, and a journey through history? Look no further than a tour of Scotland and Ireland. These two countries boast rich cultural heritage, stunning natural beauty, and countless attraction...Contact Us. Lab and Corporate Office addresses. Customer Service contact info. Media Contacts.FRIENDSWOOD, Texas--(BUSINESS WIRE)-- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has completed its acquisition of AltheaDx, Inc. (AltheaDx). AltheaDx is a commercial-stage molecular diagnostics company specializing in the field of pharmacogenomics ...Texas - Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a study in the Journal of the Advanced Practitioner in Oncology (JADPRO) that assessed the viewpoints of NPs/PAs toward the clinical use of DecisionDx-Melanoma in patients diagnosed with cutaneous melanoma.Castle Biosciences was founded by Derek Maetzold who believed that traditional methods to determine cancer patients’ prognosis could be improved by newly emerging techniques in molecular biology. We continue to focus on transforming disease management in areas of unmet clinical need through the development and marketing of innovative ...Jun 2, 2023 · Shares of Castle Biosciences ( CSTL 0.15%) closed this week down 12.6% for the week, after being down as much as 18.3% for the week, according to data provided by S&P Global Market Intelligence ... According to the issued ratings of 4 analysts in the last year, the consensus rating for Castle Biosciences stock is Buy based on the current 4 buy ratings for CSTL. The average twelve-month price prediction for Castle Biosciences is $32.29 with a high price target of $41.00 and a low price target of $25.00. Learn more on CSTL's analyst rating ...

Now $19 (Was $̶3̶8̶) on Tripadvisor: Rooms Inc Hotel, Semarang. See 316 traveler reviews, 561 candid photos, and great deals for Rooms Inc Hotel, ranked #16 of 300 hotels in …Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that data spanning its dermatologic portfolio of gene expression profile (GEP) tests was recently presented at the 2023 American Society for Dermatologic Surgery (ASDS) Annual Meeting in Chicago.Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that data spanning its dermatologic portfolio of gene expression profile (GEP) tests was recently presented at the 2023 American Society for Dermatologic Surgery (ASDS) Annual Meeting in Chicago.View the latest Castle Biosciences Inc. (CSTL) stock price, news, historical charts, analyst ratings and financial information from WSJ.National award recognizes Castle’s strong culture and employee engagement. September 19, 2023 07:00 AM Eastern Daylight Time. FRIENDSWOOD, Texas-- ( BUSINESS WIRE )--Castle Biosciences, Inc ...MyPath Melanoma has over 35,000 clinically resulted cases and 9 publications including validation to outcomes. DiffDx-Melanoma offers a neural network, artificial intelligence-designed algorithm with a low rate of intermediate results. The test was validated in cutaneous melanocytic lesions to accurately differentiate between benign and ...

April 04, 2022 04:05 PM Eastern Daylight Time. FRIENDSWOOD, Texas-- ( BUSINESS WIRE )--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide ...

ARTOTEL GROUP is built from a tremendous passion in promoting local art and creative hospitality. With wide range of hotel brands, events, and merchandise, …View the latest Castle Biosciences Inc. (CSTL) stock price, news, historical charts, analyst ratings and financial information from WSJ. If you’re planning a trip to Disney World, the Magic Kingdom is a must-see. With its iconic Cinderella Castle, thrilling rides, and classic attractions, it’s no wonder why millions of visitors flock to this beloved park each year.you invested in castle biosciences, inc. and it’s time to vote! this is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on may 25, 2023 at 10:00 a.m. edt at the omni william penn hotel, 530 william penn place, pittsburgh, pennsylvania 15219. ...Castle Biosciences Inc (CSTL) USD0.001 ; Trade low · $19.59 ; Year low · $9.26 ; Previous · $0.13 ; Volume · n/a ; Dividend yield · 0.00%.Castle Biosciences, Inc. CSTL, a company improving health through innovative tests that guide patient care, today announced new data demonstrating the significant clinical utility of its ...Castle Biosciences is a molecular diagnostics company that provides tumor-specific information for improved treatment decisions and patient outcomes.Cutaneous Squamous Cell Carcinoma. Cutaneous squamous cell carcinoma (SCC), non-melanoma skin cancer, is one of the most common cancers with an estimated incidence of more than 1,000,000 cases in the U.S. each year. Approximately 20% of patients have high-risk factors based on tumor depth, histology, anatomic location, and/or immunosuppression.

Mar 1, 2023 · Castle Biosciences, Inc. (CSTL) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $0.91. This compares to loss of $0.25 per share a year ago.

John C. Cheneval is Executive Director-Business Development at Castle Biosciences, Inc. In his past career he was Vice President-Pharma Partnerships at HTG Molecular Diagnostics, Inc. and Executive...

Castle Biosciences to acquire mental health testing co. AltheaDX in deal worth up to $140M. Friendswood-based diagnostics company Castle Biosciences Inc. (Nasdaq: CSTL) will acquire San Diego ...FRIENDSWOOD, Texas, March 10, 2023--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that new ...Castle Learning Online’s products don’t come with ready-made answer keys, but they do provide instant feedback and answers once the student has gone through an assignment.Castle Biosciences is a high growth, commercial stage molecular diagnostics company dedicated to helping patients and their physicians make the best possible decisions about their treatment and ...Castle Biosciences announced the acquisition Monday after markets closed. Its shares fell 9 percent to $41.60 in early trading Tuesday on the Nasdaq exchange. Business Latest Technology Biotech ...Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm offers DecisionDx-Melanoma ... MyPath Melanoma has over 35,000 clinically resulted cases and 9 publications including validation to outcomes. DiffDx-Melanoma offers a neural network, artificial intelligence-designed algorithm with a low rate of intermediate results. The test was validated in cutaneous melanocytic lesions to accurately differentiate between benign and ...At closing, Castle will pay $65.0 million in initial consideration to AltheaDx security holders, which will consist of $32.5 million in cash, subject to adjustments for cash, debt, transaction ...Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm offers DecisionDx-Melanoma ...Derek J. Maetzold founded Castle Biosciences in September 2007 and has served as our President and Chief Executive Officer, and as a member of our board of ...Jun 3, 2023 · FRIENDSWOOD, Texas, June 03, 2023--Castle will share new data on DecisionDx®-Melanoma and DecisionDx®-UM during the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.

Age : 54. Public asset : 2,021,277 USD. Linked companies : Castle Biosciences, Inc. Summary. Kristen M. Oelschlager is Chief Operating Officer for Castle Biosciences, Inc. Ms. Oelschlager previously held the position of Clinical Research Coordinator at Maricopa County Special Health Care District (Arizona).Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced it has signed a definitive agreement to acquire AltheaDx, Inc. (AltheaDx). AltheaDx is a commercial-stage molecular diagnostics company specializing in the field of pharmacogenomics (PGx) testing services that ...Oct 2001 - Jul 2010 8 years 10 months. I held various positions during my employment. Some of these positions included Team Leader and staff nurse OR, temp purchasing coordinator as well as seats ...Castle Biosciences announced that it has completed its acquisition of AltheaDx, Inc. Castle Biosciences Completes Acquisition of AltheaDx Acquisition expands Castle’s estimated U.S. TAM by ...Instagram:https://instagram. best small cap stocks to buy todaytsmc stock forecastfctdxfastest growing stocks 2,091.70 +34.50(+1.68%) Castle Biosciences, Inc. (CSTL) NasdaqGM - NasdaqGM Real Time Price. Currency in USD Follow 2W 10W 9M 19.97 -0.02 (-0.10%) At close: 04:00PM EST 20.35 +0.38 (+1.90%) After...About Castle Biosciences. Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. … mortgage companies in north carolinaoptionsprofit National award recognizes Castle’s strong culture and employee engagement. September 19, 2023 07:00 AM Eastern Daylight Time. FRIENDSWOOD, Texas-- ( BUSINESS WIRE )--Castle Biosciences, Inc ... webull index funds He received a B.S. degree in molecular biology from Temple University in Philadelphia. Dr. Cook is an author of many medical and scientific publications and a co-inventor of several of Castle Biosciences’ technologies. Bob Cook has served as our Senior Vice President, Research & Development since September 2020, previously serving as our Vice ...He received a B.S. degree in molecular biology from Temple University in Philadelphia. Dr. Cook is an author of many medical and scientific publications and a co-inventor of several of Castle Biosciences’ technologies. Bob Cook has served as our Senior Vice President, Research & Development since September 2020, previously serving as our Vice ...Biosaintifika was established in 2009. Title with the title Biosaintifika Berkala Ilmiah Biologi. Starting from Volume 5 Number 2 September 2013, this journal is only published three …